Search
forLearn
5 / 801 resultslearn histidine
learn myristoyl pentapeptide-17
learn riboflavin
learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Research
5 / 12 results
research 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
IL-15 helps maintain hair growth and protects the immune status of hair follicles.
research IL-15 Prolongs Anagen, Stimulates Proliferation, and Suppresses Apoptosis in the Hair Matrix of Human Scalp Hair Follicles
IL-15 helps hair grow longer and stronger by extending the growth phase and reducing cell death.
research 013 IL-15/IL-15Rα signaling is a guardian of human hair follicle immune privilege and promotes hair growth
IL-15 promotes hair growth and protects hair follicles.
research Interleukin-15 is a hair follicle immune privilege guardian
Interleukin-15 can help hair growth and protect hair follicles.
research Interleukin-25-Mediated-IL-17RB Upregulation Promotes Cutaneous Wound Healing in Diabetic Mice by Improving Endothelial Cell Functions
IL-25 helps heal diabetic wounds by improving blood vessel and skin cell functions.
Community Join
5 / 1000+ resultscommunity HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community Shiseido RCH-01
Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.